Impax Laboratories revenues surge in Q3
Impax has posted a net income of $75.16m for the third quarter 2010, or $1.15 per diluted share, compared to $6.69m, or $0.11 per diluted share, for the
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.
As per the terms of the non-exclusive alliance, Dako and Quintiles will offer integrated drug-diagnostic development services and companion diagnostic products. The first such collaboration will support AstraZeneca